Related Experiment Video

Updated: Jul 13, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Plasmid DNA and viral vector-based vaccines for the treatment of cancer

Richard J Anderson1, Joerg Schneider

  • 1Oxxon Therapeutics Ltd., 2nd Floor Florey House, 3 Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GP, UK.

Vaccine
|August 19, 2007
PubMed

Insights

This review explores plasmid DNA and viral vector cancer vaccines for delivering tumor antigens to stimulate immune responses. It summarizes clinical trial delivery systems, discusses their pros and cons, and offers future development insights.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Plasmid DNA and viral vectors are promising platforms for cancer vaccine development.
  • These vectors facilitate the delivery of tumor-specific antigens to elicit targeted immune responses.
  • Current research focuses on optimizing these systems for enhanced therapeutic efficacy.

Purpose of the Study:

  • To review the application of plasmid DNA and viral vector vaccines in cancer therapy.
  • To summarize antigen delivery systems used in recent clinical trials.
  • To discuss the advantages and disadvantages of various delivery approaches.

Main Methods:

  • Literature review of preclinical and clinical studies on DNA and viral vector cancer vaccines.
  • Analysis of antigen delivery systems and their immunomodulatory effects.
  • Comparative assessment of different vector types and their clinical performance.

Main Results:

  • Plasmid DNA and viral vectors show potential in inducing tumor-specific immune responses.
  • Various delivery systems have been evaluated in clinical trials with mixed outcomes.
  • Key advantages include antigen specificity and potential for broad applicability, while challenges involve immunogenicity and delivery efficiency.

Conclusions:

  • Plasmid DNA and viral vector vaccines represent a significant advancement in cancer immunotherapy.
  • Further research is needed to optimize delivery systems and overcome existing challenges.
  • Future development may focus on combination therapies and novel vector designs for improved cancer treatment outcomes.

More Related Videos

Production of Double-stranded DNA Ministrings06:12

Production of Double-stranded DNA Ministrings

Published on: February 29, 2016

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...